Role and rationale of gene therapy and other novel therapies in the management of NMIBC.

Journal article

Bladder cancer is the second most common urological malignancy with a one in 28 lifetime risk. Three-quarters of tumors are non-muscle-invasive (formerly termed superficial) at the time of presentation. Approximately half of all non-muscle-invasive bladder cancer (NMIBC) will recur and, depending on certain prognostic factors including grade, stage and presence of carcinoma in situ, a number will progress to muscle invasion. The standard of care for NMIBC is transurethral resection of bladder...

Expand abstract

Authors: Lojo Rial, C; Wilby, D; Sooriakumaran, P

• Journal: Expert review of anticancer therapy
• Volume: 9
• Issue: 12
• Pages: 1777-1782
• Publication date: 2009-12-01
• DOI: 10.1586/era.09.106
• EISSN: 1744-8328
• ISSN: 1473-7140
• Language: English
• Keywords: Humans; Neoplasm Staging; Antibodies, Monoclonal; Combined Modality Therapy; Animals; Urinary Bladder Neoplasms; Disease Progression; Neoplasm Invasiveness; Oncolytic Virotherapy; Prognosis; Neoplasm Recurrence, Local; Genetic Therapy